Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Lactobacillus rhamnosus LM1019 strain and composition for preventing and treating obesity or diabetes mellitus comprising same

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ أكثر حفظ في قائمتي
  • Publication Date:
    February 07, 2023
  • معلومة اضافية
    • Patent Number:
      11571,448
    • Appl. No:
      16/645185
    • Application Filed:
      September 06, 2018
    • نبذة مختصرة :
      The present invention relates to a Lactobacillus rhamnosus LM1019 strain (accession number KCCM12308P), and a composition for preventing and treating obesity or diabetes mellitus, comprising the same. Specifically, the Lactobacillus rhamnosus LM1019 strain of the present invention reduces fat cells, neutral fats, subcutaneous fats, and cholesterol, thus having an effect of preventing and treating obesity, and also reduces the blood glucose concentration and the blood insulin concentration, thereby inhibiting insulin resistance and thus having an effect of preventing and treating diabetes mellitus.
    • Inventors:
      Genome And Company (Gyeonggi-do, KR); Lactomason Co., Ltd. (Gyeongsangnam-do, KR)
    • Assignees:
      Genome and Company (Gyeonggi-do, KR), Lactomason Co., Ltd. (Gyeongsangnam-do, KR)
    • Claim:
      1. A method of ameliorating insulin resistance by reducing the concentrations of blood glucose and blood insulin comprising oral administration of an effective amount of the Lactobacillus rhamnosus LM1019 strain deposited under the accession number KCCM12308P to a subject in need thereof.
    • Claim:
      2. The method of claim 1 , wherein the subject is obese.
    • Claim:
      3. The method of claim 1 , wherein the subject has type 2 diabetes mellitus.
    • Claim:
      4. The method of claim 1 , wherein the subject is obese and has type 2 diabetes mellitus.
    • Claim:
      5. The method of claim 1 , wherein the Lactobacillus rhamnosus LM1019 strain has a lipolysis-suppressing effect in the small intestinal cells or in the digestive tract and an appetite-regulating effect simultaneously.
    • Claim:
      6. The method of claim 5 , wherein the lipolysis-suppressing effect is achieved by inhibiting lipase activity.
    • Claim:
      7. The method of claim 5 , wherein the appetite-regulating effect is achieved by reducing the secretion of the hormone leptin.
    • Claim:
      8. The method of claim 5 , wherein the Lactobacillus rhamnosus LM1019 strain has an insulin resistance-reducing effect.
    • Claim:
      9. The method of claim 1 , wherein the Lactobacillus rhamnosus LM1019 strain is provided in a food composition or in a pharmaceutical composition.
    • Claim:
      10. The method of claim 9 , wherein the food composition is a health functional food, a dairy product, a fermented product, or a food additive.
    • Claim:
      11. The method of claim 1 , wherein the Lactobacillus rhamnosus LM1019 strain is provided in an animal feed composition.
    • Patent References Cited:
      20150283186 October 2015 Grompone et al.
      2016520305 July 2016
      101611837 April 2016
      101736033 May 2017
      101864347 June 2018
      2015172191 November 2015


    • Other References:
      Kemgang et al. J. Nutr. Biochem. 30: 62-73, 2016. cited by examiner
      Sharma et al. AGE 36: 29686, pp. 1-17, 2014. cited by examiner
      Lee, Hui-Young , et al., “Human originated bacteria, Lactobacillus rhamnosus PL60, produce conjugated linoleic acid and show anti-obesity effects in diet-induced obese mice”, Elsevier—Biochimica et Biophysica Acta 1761 (2006), May 20, 2006, 736-744. cited by applicant
    • Primary Examiner:
      Devi, S.
    • Attorney, Agent or Firm:
      Servilla Whitney LLC
    • الرقم المعرف:
      edspgr.11571448